Multiple asset management firms increased their positions in the Johnson & Johnson company, according to the compilation of recent news. With an investment of $2 billion, the company is set to stimulate US manufacturing, potentially anticipating looming drug tariffs. The organization's efforts against Alzheimer’s disease and the provision of resources for patients at risk of developing multiple myeloma are noteworthy. Positive data from the fight against AFib and treatment results along with receiving a US FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer show the company's innovative and impactful strides in healthcare. Johnson & Johnson also gained recognition being named to Fortune’s 2025 America’s Most Innovative Companies list, twice. The company also plans to enhance the training and education of Health Workers Globally, unveiling its participation in the inauguration of the World Health Organization (WHO) Academy. Other significant mentions include exceeding earnings expectations, improving cardiac device sales, a 7.2% increase since the last earnings report, and a bright 2025 forecast alongside halved tariff cost outlook.
Johnson Johnson JNJ News Analytics from Tue, 15 Oct 2024 07:00:00 GMT to Sun, 07 Sep 2025 00:02:14 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
